188 related articles for article (PubMed ID: 37312466)
1. [Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].
Zhou QF; Luo Y; He TY; Ling JY; Xu YB; Yang J; Xia Y
Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):538-542. PubMed ID: 37312466
[No Abstract] [Full Text] [Related]
2. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.
Zhang J; Sun L; Shi X; Li S; Liu C; Li X; Lu M; Deng J; Tan X; Guan W; Li G; Wen X; Liu P; Li C
Arthritis Res Ther; 2023 Oct; 25(1):204. PubMed ID: 37853451
[TBL] [Abstract][Full Text] [Related]
3. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Yu Z; Wang L; Quan M; Zhang T; Song H
Rheumatology (Oxford); 2021 Apr; 60(4):1700-1707. PubMed ID: 33024992
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment with tofacitinib for anti-melanoma differentiation-associated gene 5 antibody-positive juvenile dermatomyositis: case reports and review of the literature.
Yamazaki S; Shimizu M; Yakabe A; Inage E; Jimbo K; Suzuki M; Miyaoka F; Kaneko S; Irabu H; Shimbo A; Ohtomo Y; Mori M; Morio T; Shimizu T
Immunol Med; 2024 Jun; 47(2):110-117. PubMed ID: 38557269
[TBL] [Abstract][Full Text] [Related]
5. Juvenile dermatomyositis associated with autoantibodies to small ubiquitin-like modifier activating enzyme: a report of 4 cases from North India and a review of literature.
Vignesh P; Barman P; Basu S; Mondal S; Ishran B; Kumrah R; Dod A; Garg R; Rawat A; Singh S
Immunol Res; 2023 Feb; 71(1):112-120. PubMed ID: 36278969
[TBL] [Abstract][Full Text] [Related]
6. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
7. Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Lanis A; Volochayev R; Kleiner DE; Vittal A; Heller T; Rider LG; Shenoi S
Pediatr Rheumatol Online J; 2022 Apr; 20(1):30. PubMed ID: 35443665
[TBL] [Abstract][Full Text] [Related]
8. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
Giancane G; Lavarello C; Pistorio A; Oliveira SK; Zulian F; Cuttica R; Fischbach M; Magnusson B; Pastore S; Marini R; Martino S; Pagnier A; Soler C; Staņēvicha V; Ten Cate R; Uziel Y; Vojinovic J; Fueri E; Ravelli A; Martini A; Ruperto N;
Pediatr Rheumatol Online J; 2019 May; 17(1):24. PubMed ID: 31118099
[TBL] [Abstract][Full Text] [Related]
9. Features distinguishing clinically amyopathic juvenile dermatomyositis from juvenile dermatomyositis.
Mamyrova G; Kishi T; Targoff IN; Ehrlich A; Curiel RV; Rider LG;
Rheumatology (Oxford); 2018 Nov; 57(11):1956-1963. PubMed ID: 30016492
[TBL] [Abstract][Full Text] [Related]
10. Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Sherman MA; Kim H; Banschbach K; Brown A; Gewanter HL; Lang B; Perron M; Robinson AB; Spitznagle J; Stingl C; Syverson G; Tory HO; Spencer CH; Tarvin SE
Pediatr Rheumatol Online J; 2023 Jan; 21(1):3. PubMed ID: 36609397
[TBL] [Abstract][Full Text] [Related]
11. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
[TBL] [Abstract][Full Text] [Related]
12. Juvenile dermatomyositis: a tertiary center experience.
Barut K; Aydin PO; Adrovic A; Sahin S; Kasapcopur O
Clin Rheumatol; 2017 Feb; 36(2):361-366. PubMed ID: 28058540
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA
Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482
[TBL] [Abstract][Full Text] [Related]
14. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.
Hinze CH; Speth F; Oommen PT; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):38. PubMed ID: 29925381
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical and laboratory features and treatment responses in patients with clinically amyopathic juvenile dermatomyositis and classical juvenile dermatomyositis.
Gezgin Yıldırım D; Baglan E; Güngörer V; Yıldız C; Tuncez S; Bülbül M; Acar B; Bakkaloğlu SA
Int J Rheum Dis; 2023 Aug; 26(8):1504-1511. PubMed ID: 37288472
[TBL] [Abstract][Full Text] [Related]
16. Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series.
Toplak N; Pimpale Chavan P; Rosina S; Dallos T; Rotem Semo O; Aguiar CL; Khubchandani R; Ravelli A; Patwardhan A
Front Pediatr; 2021; 9():810785. PubMed ID: 35280444
[TBL] [Abstract][Full Text] [Related]
17. [Three cases report of juvenile dermatomyositis with positive anti-melanoma differentiation associated gene 5 (MDA5) antibody and severe interstitial lung disease and literature review].
Hou J; Zhou ZX; Li JG; Xu YJ; Ding YC
Zhonghua Er Ke Za Zhi; 2019 Dec; 57(12):928-933. PubMed ID: 31795559
[No Abstract] [Full Text] [Related]
18. [Clinical characteristics of juvenile dermatomyositis complicated with interstitial lung disease].
Chen L; Hu Y; Yao Y; Zhen XF; Chen F; He Q; Mo X; Ma SC
Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):465-9. PubMed ID: 22931947
[TBL] [Abstract][Full Text] [Related]
19. Is juvenile dermatomyositis a different disease in children up to three years of age at onset than in children above three years at onset? A retrospective review of 23 years of a single center's experience.
Patwardhan A; Rennebohm R; Dvorchik I; Spencer CH
Pediatr Rheumatol Online J; 2012 Sep; 10(1):34. PubMed ID: 22995763
[TBL] [Abstract][Full Text] [Related]
20. The arthritis of inflammatory childhood myositis syndromes.
Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
